Potential Roles of α-amylase in Alzheimer's Disease: Biomarker and Drug Target.
Curr Neuropharmacol
; 20(8): 1554-1563, 2022.
Article
em En
| MEDLINE
| ID: mdl-34951390
ABSTRACT
Alzheimer's disease (AD), the most common form of dementia, is pathologically characterized by the deposition of amyloid-ß plaques and the formation of neurofibrillary tangles. In a neurodegenerative brain, glucose metabolism is also impaired and considered as one of the key features in AD patients. The impairment causes a reduction in glucose transporters and the uptake of glucose as well as alterations in the specific activity of glycolytic enzymes. Recently, it has been reported that α-amylase, a polysaccharide-degrading enzyme, is present in the human brain. The enzyme is known to be associated with various diseases such as type 2 diabetes mellitus and hyperamylasaemia. With this information at hand, we hypothesize that α-amylase could have a vital role in the demented brains of AD patients. This review aims to shed insight into the possible link between the expression levels of α-amylase and AD. Lastly, we also cover the diverse role of amylase inhibitors and how they could serve as a therapeutic agent to manage or stop AD progression.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Tipo 2
/
Doença de Alzheimer
Limite:
Humans
Idioma:
En
Revista:
Curr Neuropharmacol
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Malásia